The US Food and Drug Administration has approved the proton pump inhibitor, Nexium (esomeprazole sodium), for use in children one month and older for the short-term treatment of gastroesophageal reflux disease, AstraZeneca announced. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
